FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3087788868> ?p ?o ?g. }

• W3087788868 endingPage "S939" @default.
• W3087788868 startingPage "S939" @default.
• W3087788868 abstract "Gemcitabine and nab-paclitaxel (NPG) is one of the standard 1st therapies for metastatic pancreatic cancer (mPC). Nevertheless, only few data exist on health-related quality of life (QoL) in mPC. receiving first-line systemic chemotherapy. The QOLIXANE-PARAGON study is a prospective, non-interventional, multicenter sub-study of the PARAGON- registry, conducted in Germany and transitioned into a permanent registry for pancreatic cancer pts considering all types of treatments. This report focuses on the pts enrolled into the QOLIXANE portion of the study, treated with NPG in 1st line. Pts were recruited from 95 German centers. QoL was prospectively measured via EORTC-C30 questionnaires (at baseline and every month thereafter): therapy and efficacy parameters were prospectively collected. QoL and efficacy endpoints were analyzed in the intention-to-treat population (ITT). Main objectives were the rate of patients without deterioration of Global Health Status/QoL (GHS/QoL) at 3 and 6 months. 600 pts were enrolled. MPFS was 5.85 months (95% CI, 5.23 to 6.25). MOS was 8.91 mo (95% CI, 7.89 to 10.19). The mOS in ECOG 0 pts. was significantly better (11.18 mo; p = 0.027) than in ECOG 1 pts. (mOS 8.52 mo) and ECOG 2 (mOS 4.80 mo; p <0.0001). Worst mOS was seen in ECOG 3 (mOS 2.94 mo). The KM-analysis showed that 61% and 41% of pts had maintained QoL/GHS after 3 and 6 months, respectively. Median time to deterioration of QoL/GHS was 4.68 months (95% CI, 4.04 to 5.59). Mean QoL/GHS improved from 46.1 (SD 22.7) at baseline to 52.8 (SD 21.3) after 6 months. In the QoL response analysis, 34.6%, 37.4% and 28% of evaluable pts had improved, stable and worse QoL/GHS after 3 months, respectively. In the Cox regression analysis, GHS/QoL scores strongly predicted survival with a HR of 0.86 (p<0.0001). QoliXane is the largest study on QoL in mPC and shows that time to deterioration of QoL is short, reflecting the aggressive nature of mPC. Nevertheless, a relevant group of mPC in 1st line have improved or maintained QoL after 3 and 6 months, indicating that QoL is a predictor of pts outcome." @default.
• W3087788868 created "2020-10-01" @default.
• W3087788868 creator A5002180921 @default.
• W3087788868 creator A5003615636 @default.
• W3087788868 creator A5004519568 @default.
• W3087788868 creator A5005554580 @default.
• W3087788868 creator A5021230294 @default.
• W3087788868 creator A5035093957 @default.
• W3087788868 creator A5038203688 @default.
• W3087788868 creator A5038723818 @default.
• W3087788868 creator A5043901757 @default.
• W3087788868 creator A5048013654 @default.
• W3087788868 creator A5053037783 @default.
• W3087788868 creator A5055092398 @default.
• W3087788868 creator A5061424072 @default.
• W3087788868 creator A5069481844 @default.
• W3087788868 creator A5070309355 @default.
• W3087788868 creator A5072204336 @default.
• W3087788868 creator A5073286593 @default.
• W3087788868 creator A5079645039 @default.
• W3087788868 creator A5082309872 @default.
• W3087788868 creator A5082822513 @default.
• W3087788868 date "2020-09-01" @default.
• W3087788868 modified "2023-09-27" @default.
• W3087788868 title "1525O The QOLIXANE trial - Real life QoL and efficacy data in 1st line pancreatic cancer from the prospective platform for outcome, quality of life, and translational research on pancreatic cancer (PARAGON) registry" @default.
• W3087788868 doi "https://doi.org/10.1016/j.annonc.2020.08.2008" @default.
• W3087788868 hasPublicationYear "2020" @default.
• W3087788868 type Work @default.
• W3087788868 sameAs 3087788868 @default.
• W3087788868 citedByCount "0" @default.
• W3087788868 crossrefType "journal-article" @default.
• W3087788868 hasAuthorship W3087788868A5002180921 @default.
• W3087788868 hasAuthorship W3087788868A5003615636 @default.
• W3087788868 hasAuthorship W3087788868A5004519568 @default.
• W3087788868 hasAuthorship W3087788868A5005554580 @default.
• W3087788868 hasAuthorship W3087788868A5021230294 @default.
• W3087788868 hasAuthorship W3087788868A5035093957 @default.
• W3087788868 hasAuthorship W3087788868A5038203688 @default.
• W3087788868 hasAuthorship W3087788868A5038723818 @default.
• W3087788868 hasAuthorship W3087788868A5043901757 @default.
• W3087788868 hasAuthorship W3087788868A5048013654 @default.
• W3087788868 hasAuthorship W3087788868A5053037783 @default.
• W3087788868 hasAuthorship W3087788868A5055092398 @default.
• W3087788868 hasAuthorship W3087788868A5061424072 @default.
• W3087788868 hasAuthorship W3087788868A5069481844 @default.
• W3087788868 hasAuthorship W3087788868A5070309355 @default.
• W3087788868 hasAuthorship W3087788868A5072204336 @default.
• W3087788868 hasAuthorship W3087788868A5073286593 @default.
• W3087788868 hasAuthorship W3087788868A5079645039 @default.
• W3087788868 hasAuthorship W3087788868A5082309872 @default.
• W3087788868 hasAuthorship W3087788868A5082822513 @default.
• W3087788868 hasBestOaLocation W30877888681 @default.
• W3087788868 hasConcept C121608353 @default.
• W3087788868 hasConcept C126322002 @default.
• W3087788868 hasConcept C141071460 @default.
• W3087788868 hasConcept C159110408 @default.
• W3087788868 hasConcept C188816634 @default.
• W3087788868 hasConcept C2778527826 @default.
• W3087788868 hasConcept C2779951463 @default.
• W3087788868 hasConcept C2780210213 @default.
• W3087788868 hasConcept C2780258809 @default.
• W3087788868 hasConcept C2908647359 @default.
• W3087788868 hasConcept C535046627 @default.
• W3087788868 hasConcept C71924100 @default.
• W3087788868 hasConcept C99454951 @default.
• W3087788868 hasConceptScore W3087788868C121608353 @default.
• W3087788868 hasConceptScore W3087788868C126322002 @default.
• W3087788868 hasConceptScore W3087788868C141071460 @default.
• W3087788868 hasConceptScore W3087788868C159110408 @default.
• W3087788868 hasConceptScore W3087788868C188816634 @default.
• W3087788868 hasConceptScore W3087788868C2778527826 @default.
• W3087788868 hasConceptScore W3087788868C2779951463 @default.
• W3087788868 hasConceptScore W3087788868C2780210213 @default.
• W3087788868 hasConceptScore W3087788868C2780258809 @default.
• W3087788868 hasConceptScore W3087788868C2908647359 @default.
• W3087788868 hasConceptScore W3087788868C535046627 @default.
• W3087788868 hasConceptScore W3087788868C71924100 @default.
• W3087788868 hasConceptScore W3087788868C99454951 @default.
• W3087788868 hasLocation W30877888681 @default.
• W3087788868 hasOpenAccess W3087788868 @default.
• W3087788868 hasPrimaryLocation W30877888681 @default.
• W3087788868 hasRelatedWork W1975243149 @default.
• W3087788868 hasRelatedWork W2002483815 @default.
• W3087788868 hasRelatedWork W2073827132 @default.
• W3087788868 hasRelatedWork W2319496893 @default.
• W3087788868 hasRelatedWork W2762135872 @default.
• W3087788868 hasRelatedWork W2886854042 @default.
• W3087788868 hasRelatedWork W2993595907 @default.
• W3087788868 hasRelatedWork W4212799941 @default.
• W3087788868 hasRelatedWork W4242945331 @default.
• W3087788868 hasRelatedWork W2780792851 @default.
• W3087788868 hasVolume "31" @default.
• W3087788868 isParatext "false" @default.
• W3087788868 isRetracted "false" @default.
• W3087788868 magId "3087788868" @default.
• W3087788868 workType "article" @default.